First Round News Hubb
Advertisement Banner
  • Home
  • First Round News
  • Funding News
  • Contact
No Result
View All Result
  • Home
  • First Round News
  • Funding News
  • Contact
No Result
View All Result
First Round News Hubb
No Result
View All Result
Home First Round News

The Capital Quest | Amicus, Kotak PE invest in Bharat Serums founder’s medical testing venture

admin by admin
November 7, 2022
in First Round News


Private equity firms Amicus Capital and Kotak Investment Advisors Ltd have joined hands to invest an undisclosed amount in a three-year-old venture founded by the erstwhile promoter of Bharat Serums & Vaccines, Bharat Daftary.

Rivaara Labs, a testing services and research and development-focused molecular diagnostics (MDx) company, said Monday it has raised its first institutional round of equity led by the two PE firms.

Bharat Daftary, the founder of Rivaara, also participated in the round.

Rivaara is a vertically integrated MDx company founded in 2019 that has developed PCR-based test kits in collaboration with European research labs. These tests, which are specifically developed for detecting pathogens prevalent in India, seeks to lead to early and effective treatments to save lives.

These products will also look to reduce the misuse of antibiotics which has led to the growing problem of antibiotic-resistant strains. Tests respiratory diseases, sepsis, TB, anti-microbial resistance, etc. will initially be made available through Rivaara’s own molecular diagnostic lab network.

The company plans to expand its network from 12 labs to around 60 labs across India, providing faster turnaround time to patients. Eventually, the kits will be made available to other diagnostics players and Rivaara will also tap into the international markets.

Rivaara said it also offers point-of-care products for patented novel biomarkers and manufactures reagents / enzymes with application in molecular biology and proteomic research. It plans to use the proceeds from the current round of fund raise to accelerate the development and commercialization of proprietary test kits, upgrade the manufacturing facilities and expand its lab network besides scaling up its talent base.

“The vision for Rivaara is to positively impact patient care by addressing gaps in widespread adoption of molecular diagnostics through a scientific sales force to create the right awareness, presence of local labs for faster processing of samples and international quality kits at affordable prices,” Daftary said.

Daftary had sold Bharat Serums to private equity firm Advent International three years ago.

Dhiraj Rajendran, Executive Director, Kotak Investment Advisors, said, “Advances in molecular diagnostics over the last few years have opened up possibilities for faster and more accurate ways to detect pathogens at affordable price points. Adoption of some of these advances such as RT-PCR tests was witnessed during response to Covid-19 pandemic.”

Rivaara is Amicus Capital’s eleventh investment from its maiden fund that had raised $88 million (Rs 636 crore). It had earlier invested across companies in financial services, technology, and consumer industries.

Related



Source link

Previous Post

WPP announces its first Campus in Brazil

Next Post

Lina Energy grabs £3M for its cobalt and lithium-free solid-state sodium battery

Next Post

Lina Energy grabs £3M for its cobalt and lithium-free solid-state sodium battery

Recommended

How to Write a Cover Letter for Your Data Room

4 weeks ago

Avenda health ropes in $10M to cure prostate cancer via AI

5 months ago

Click fraud detection firm Polygraph identifies over one hundred

3 months ago

Infobip Appoints Vice President of Marketing and Growth to Support

2 months ago

Jeff Bezos-backed food tech unicorn, NotCo gobbles $70M to fuel new B2B platform

1 month ago

Mirriad Announces New Partnership with The Shade Room

4 months ago

first-round-white

© 2022 First Round News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • First Round News
  • Funding News
  • Contact

Newsletter Sign Up.

No Result
View All Result
  • Home
  • First Round News
  • Funding News
  • Contact

© 2022 First Round News Hubb All rights reserved.